163 related articles for article (PubMed ID: 28422376)
1. Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C.
Sato K; Kobayashi T; Yamazaki Y; Takakusagi S; Horiguchi N; Kakizaki S; Kusano M; Yamada M
Hepatol Res; 2017 Nov; 47(12):1346-1353. PubMed ID: 28422376
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus reactivation after successful treatment of hepatitis C virus with sofosbuvir and ribavirin: A case report and literature review.
Miyasaka A; Yoshida Y; Suzuki A; Masuda T; Okamoto H; Takikawa Y
Medicine (Baltimore); 2020 Oct; 99(41):e22650. PubMed ID: 33031326
[TBL] [Abstract][Full Text] [Related]
3. Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy.
Tamori A; Abiru S; Enomoto H; Kioka K; Korenaga M; Tani J; Enomoto M; Sugiyama M; Masaki T; Kawada N; Yatsuhashi H; Nishiguchi S; Mizokami M
J Viral Hepat; 2018 May; 25(5):608-611. PubMed ID: 29194858
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
Fabbri G; Mastrorosa I; Vergori A; Mazzotta V; Pinnetti C; Grisetti S; Zaccarelli M; Ammassari A; Antinori A
BMC Infect Dis; 2017 Mar; 17(1):182. PubMed ID: 28249574
[TBL] [Abstract][Full Text] [Related]
5. Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin.
Preda CM; Popescu CP; Baicus C; Constantinescu I; Oproiu A; Voiosu T; Diculescu M; Negreanu L; Gheorghe L; Sporea I; Trifan A; Ceausu E; Proca D; Manuc M
J Viral Hepat; 2018 Jul; 25(7):834-841. PubMed ID: 29397016
[TBL] [Abstract][Full Text] [Related]
6. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?
Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Nishimura D; Goto H; Hirooka Y
Clin J Gastroenterol; 2016 Aug; 9(4):252-6. PubMed ID: 27329484
[TBL] [Abstract][Full Text] [Related]
7. Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy.
Majeed NA; Alawad AS; Liem KS; Takyar V; Alter H; Feld JJ; Janssen HLA; Ghany MG
Dig Dis Sci; 2023 Jul; 68(7):3193-3198. PubMed ID: 37022602
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection.
Takayama H; Sato T; Ikeda F; Fujiki S
Hepatol Res; 2016 Mar; 46(5):489-91. PubMed ID: 26297529
[TBL] [Abstract][Full Text] [Related]
10. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
Kawagishi N; Suda G; Onozawa M; Kimura M; Maehara O; Ohara M; Izumi T; Umemura M; Ito J; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
J Viral Hepat; 2017 Dec; 24(12):1098-1106. PubMed ID: 28632923
[TBL] [Abstract][Full Text] [Related]
11. Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy.
Kawagishi N; Suda G; Sakamori R; Matsui T; Onozawa M; Yang Z; Yoshida S; Ohara M; Kimura M; Kubo A; Maehara O; Fu Q; Hosoda S; Tokuchi Y; Suzuki K; Nakai M; Sho T; Morikawa K; Natsuizaka M; Ogawa K; Sakai H; Ohnishi S; Baba M; Takehara T; Sakamoto N
Sci Rep; 2022 Oct; 12(1):16800. PubMed ID: 36207368
[TBL] [Abstract][Full Text] [Related]
12. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C.
Aggeletopoulou I; Konstantakis C; Manolakopoulos S; Triantos C
World J Gastroenterol; 2017 Jun; 23(24):4317-4323. PubMed ID: 28706414
[TBL] [Abstract][Full Text] [Related]
13. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
[TBL] [Abstract][Full Text] [Related]
14. Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
Yanny BT; Latt NL; Saab S; Han S; Choi G; Kramer J; Sahota AK
J Clin Gastroenterol; 2018; 52(10):908-912. PubMed ID: 29334502
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.
Holmes JA; Yu ML; Chung RT
Expert Opin Drug Saf; 2017 Jun; 16(6):651-672. PubMed ID: 28471314
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals.
Belperio PS; Shahoumian TA; Mole LA; Backus LI
Hepatology; 2017 Jul; 66(1):27-36. PubMed ID: 28240789
[TBL] [Abstract][Full Text] [Related]
17. Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial.
Cheng PN; Liu CJ; Chen CY; Tseng KC; Lo CC; Peng CY; Lin CL; Chiu HC; Chiu YC; Chen PJ
Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2800-2808. PubMed ID: 34864158
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B Reactivation Following Eradication of HCV with Direct-Acting Antiviral Drugs (DAAs) in a Cohort of Patients from Different Institutions in Egypt.
Abdelbary MS; Samir R; El-Nahaas SM; Shahin RMH; El-Sayed M; Gaber Y; Tantawi O; Zayed NA; Yosry A
J Clin Exp Hepatol; 2022; 12(5):1276-1284. PubMed ID: 36157140
[TBL] [Abstract][Full Text] [Related]
19. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K
Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152
[TBL] [Abstract][Full Text] [Related]
20. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
